Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis.

Serum liver fibrosis markers, particularly in CIV, appeared to be reliable biomarkers of disease progression and liver decompensation in patients with compensated cirrhosis with varying etiologies.